Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management
American Journal of Hematology · 2024-06 · 99 (6) · 1142-1165
DOI: 10.1002/ajh.27271 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 07.03.2024. Verfasst von Mrinal M Patnaik und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Center for Biomedical Informatics and Information Technology.
Abstract (Originalsprache)
Disease Overview Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, characterized by prominent monocytosis and an inherent risk for leukemic transformation (~15%–20% over 3–5 years). Diagnosis Newly revised diagnostic criteria include sustained (>3 months) peripheral blood (PB) monocytosis (≥0.5 × 10 9 /L; monocytes ≥10% of leukocyte count), consistent bone marrow (BM) morphology, 95% harbor somatic mutations: TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%), RAS pathway (~30%), and others. The presence of ASXL1 and DNMT3A mutations and absence of TET2 mutations negatively impact overall survival ( ASXL1 WT / TET2 MT genotype being favorable). Risk Stratification Several risk models serve similar purposes in identifying high‐risk patients that are considered for allogeneic stem cell transplant (ASCT) earlier than later. Risk factors in the Mayo Molecular Model (MMM) include presence of truncating ASXL1 mutations, absolute monocyte count >10 × 10 9 /L, hemoglobin
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Mrinal M Patnaik, Ayalew Tefferi
Förderung
- NCI NIH HHS
- Center for Biomedical Informatics and Information Technology
Zitieren
APA
Patnaik, M. M., & Tefferi, A. (2024). Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. American Journal of Hematology, 99(6), 1142-1165. https://doi.org/10.1002/ajh.27271
Vancouver
Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. American Journal of Hematology. 2024;99(6):1142-1165. doi:10.1002/ajh.27271
BibTeX
@article{Patnaik2024,
author = {Patnaik, Mrinal M and Tefferi, Ayalew},
title = {Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {6},
pages = {1142--1165},
doi = {10.1002/ajh.27271}
}
EUVIMED